BRIEF-Theratechnologies says 82.5 pct patients achieved primary endpoint in Phase III ibalizumab trial

Tue May 24, 2016 7:24am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 24 (Reuters) - Theratechnologies Inc

* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase III ibalizumab trial

* Says taimed plans to submit an abstract to present these results at a major scientific conference later this year Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)